CAR T-Cell Therapy MuMalaysia
Kuronga kushanyira Malaysia kurapwa kweCAR T?
Tora fungidziro kubva kuzvipatara zvepamusoro muMalaysia.
CAR T cell therapy, a groundbreaking immunotherapy, is making strides in Malaysia’s medical landscape. This innovative treatment involves genetically modifying a patient’s T cells to recognize and attack cancer cells. Although initially available primarily in developed countries, Malaysia’s healthcare sector is embracing this cutting-edge approach. Several hospitals and research centers are exploring CAR T cell therapy’s potential, offering hope for patients with certain types of blood cancers, like leukemia and lymphoma. Challenges persist, including cost and infrastructure, but collaborations between institutions and industry aim to broaden access. As Malaysia advances in biotechnology and healthcare, CAR T cell therapy promises a transformative impact on cancer care.
MALAYSIAN Genomics Resource Center Bhd (MGRC) inotarisira kugadzira yayo chimeric antigen receptor (CAR) T-Cell therapy kurapwa kunowanikwa muMalaysia nemari isingasviki RM200,000 kureva mari inosvika $45,000 USD, inova chikamu chidimbu chemutengo wekurapa muEurope nekuUnited States. Ndinovimba kurapwa kweCAR T-Cell kuMalaysia kuchaunza mufaro kuzviuru zvevarwere vari kutarisira kuwana kurapwa uku.
Mufananidzo: CAR T Cell therapy yakagadziridzwa kune mamwe marudzi emamota akasimba zvakare
Sekureva kwaMalasian Genomics CEO Sasha Nordin, kambani iyi yakabatana neChina ICARTAB Biomedical Co Ltd, iyo iri kuvandudza tekinoroji iyi chete yezvirwere zvakasimba, zvisinei nekuti marapiro akafanana ezvirwere zvemvura kana ropa atove kuwanikwa munyika dzekuMadokero.
"Kuvandudza kuwanikwa kwezvinhu zvitsva chikamu chezvatinoda." Takakwanisa kusvika pachibvumirano chinotibvumira kuti tivepo kune varwere muSoutheast Asia nokuda kwechikamu chemutengo.
Muhurukuro neThe Malaysian Reserve nezuro, akati, "Tiri kushanda kuti iwanikwe nemari isingasviki RM200,000 maringe neUS$400,000 (RM1.61 miriyoni) zvishoma muEurope nekuUS."
MGRC ichava muparidzi wepamutemo weCAR T-Cell kurapwa muSingapore, Brunei, Indonesia, Thailand, Vietnam, Cambodia, neLaos, kuwedzera kuMalaysia.
Sekureva kwaSasha Omar, kambani parizvino ine mishonga yezvirwere zvitanhatu zvepamusoro gumi mudunhu, kusanganisira chiropa, pancreatic, mesothelioma, esophagus, uropi, uye mamota emudumbu. Anoti CAR T-cell immunotherapy nokuti gomarara rakasimba haisi mishonga inogadzirwa nevakawanda.
Kurapwa kwese kuri mukurapa kwakasiyana nemurwere sezvo kunosanganisira kubvisa masero emurwere uye kubvumira T-sero remurwere, sero chena reropa rakakosha mu immune system, kuziva bundu.
Iyo T-sero inozodzoserwa mumuviri wemurwere kuti ione uye kurwisa sero rakashata, kudzivirira kuti risapararira.
"Nguva yese yatinosangana nemurwere, tinofanirwa kuita chirongwa chekuongorora kana ari munhu akakodzera kurapwa neCAR T-Cell." Kana vakasangana nemaitiro ese, isu tichagadzira T-seli chete kumurwere iyeye.
"Ndosaka tichitenda kuti zvakakosha kuti zviite kuti zvive nyore." Isu tinokwanisa kudzora mitengo zvirinani nekuisa yedu lab,” akadaro.
Sasha Omar akataura kuti marabhoritari matsva ekambani iyi achange achishanda mukupera kwaKurume gore rino, uye kuti zviitiko zvichatanga zvakare nekukasira kuzadzisa kudiwa kwekurapa.
Iyo itsva 12,000 sq ft nzvimbo ichave iri muKota Damansara, nerabhoritari inotora kutenderedza 7,000 sq ft yenzvimbo uye chimiro chehofisi ichitora nzvimbo yasara.
Mishonga ichangobva kugadzirwa, yakadai seCAR-T (chimeric antigen receptor T-cell), mishonga inoshandura hupenyu hwevanhu vakapedza nzira dzavo dzokurapa. Iyi yekucheka-kumucheto marapirwo inopihwa nenzira dzisiri dzechinyakare, kusanganisira refu, yakaoma, uye yakanyanya kurongeka akatevedzana ezviitiko mukati mezvivakwa zvevanopa hutano. Vanopa rubatsiro vachabatsirikana nemishonga iyi nenzira dzakasiyana-siyana, kubva mukusimudzira mukurumbira wavo sesangano repamusoro-soro kusvika pakupa zvirongwa zvinounza mari yakawanda. Nekudaro, kuendesa aya achangoburwa marapirwo epamberi anoisa akakosha emari uye ekushandisa matambudziko kana akasanyatsoongororwa uye akagadzirirwa.
Chii chinonzi CAR T-Cell therapy (Chimeric antigen receptors)?
CAR T-Cell kurapa inzira yemununotherapy inoshandisa zvakanyatsogadziriswa T-maseru ayo ari chikamu chemuviri wedu wekuzvidzivirira ku kurwisa kenza. A sample of patients T cells are collected from the blood, then it is modified to produce special structures called chimeric antigen receptors (CAR) on their surface. When these modified CAR cells are reinfused in the patient, these new cells attack the specific antigen and kill the tumarara masero.
CAR T-Cell kurapwa inoshanda sei?
CAR T-cell therapy takes help from body’s own immune system to attack and kill cancer cells. This is done by removing some specified cells from the blood of the patient, modifying them in the lab and re-injecting them into the patient. CAR T-cell therapy has produced very encouraging results in Asiri-Hodgkin lymphoma and thus approved by FDA.
Vanokodzera vanoda CAR T-Cell therapy
At present FDA has approved CAR T-Cell therapy for some forms of aggressive and refractory Non-Hodgkin lymphoma, Myeloma uye akadzokorora uye refractory acute lymphoblastic leukemia. Murwere anofanirwa kutumira mishumo yekurapa yakazara kuti aone kushandiswa kweCAR T-Cell kurapwa kwake.
Inosanganisira maitiro eCAR T-cell therapy:
1. Varwere vane CD19 + B-cell Lymphoma (Angangoita 2 pamberi musanganiswa chemotherapy maitiro)
2. Kuva ane makore matatu kusvika makumi manomwe nemashanu ekuberekwa
3. ECOG zvibodzwa ≤2
4. Vakadzi vane mukana wekubereka vanofanirwa kunge vane weti pamuviri bvunzo yakatorwa uye yakaratidza kusagadzikana pamberi pekurapwa. Vese varwere vanobvuma kushandisa nzira dzakavimbika dzekudzivirira kubata pamuviri panguva yekutongwa uye kusvika pakutevera kekupedzisira.
Kuregera maitiro eCAR T-cell kurapa:
1. Intracranial neBP kana kufenda
2. Kutadza kufema
3. Yakaparadzirwa intravascular coagulation
4. Hematosepsis kana Utachiona husingadzoreki hunoshanda
5. Kusadzora chirwere cheshuga
Kubatsira kweCAR T-Cell kurapa
- > 5000 CAR T makesi anoitwa nachiremba ane hunyanzvi.
- Zvipatara muChina zvakagadzira mamwe maCAR T Cell mhando dzinosanganisira CD19 & CD 22 ipapo chero imwe nyika pasi.
- China iri kuitisa zvinopfuura mazana matatu emakiriniki ekuedzwa paCAR T Cell therapy. Kupfuura chero imwe nyika pasi.
- Clinical mhedzisiro yeCAR T Cell yakafanana neiyo muUSA kana chero imwe nyika uye dzimwe nguva zvirinani.
Kurapa kweCAR T-Cell kurapa
- Zadzisa ongororo yemurwere
- T-cell kuunganidzwa kubva mumuviri
- T-maseru anobva agadzirwa murabhorari
- MaT-Cell akagadzirwa nemajini anobva awedzerwa nekushandisa kukura mumarabhoritari. Aya maseru anotonhorwa otumirwa kunzvimbo dzinorapa.
- Asati akanganisa, murwere anogona kupihwa chemotherapy yekenza yavo. Izvi zvinobatsira kurapwa kurapa nenzira iri nani.
- Nguva pfupi yapfuura chemotherapy CAR T-Masero inopindirwa nemaitiro akafanana nekuisirwa ropa.
- Pane mwedzi 2-3 wekudzora nguva yemurwere.
Nguva yakatarwa yeCAR T-Cell kurapa
1. Kuongorora & kuyedza: vhiki imwe
2. Pre-kurapwa & T-Cell Kuunganidzwa: vhiki imwe
3. Kugadzirira kweT-Cell & kudzoka: mavhiki maviri-matatu
4. 1st Kubudirira kuongorora: vhiki nhatu
5. Yechipiri Kubudirira kuongorora: mavhiki matatu
Mutengo weCAR T-Cell kurapwa muMalaysia
Mutengo weCAR T-Cell kurapa muMalaysia ungangoita pakati $ 45000 - 50,000 USD. Kuti uwane ruzivo rwekukodzera maitiro uye fungidziro yemutengo ndapota tumira marepoti ako ekurapwa kune info@cancerfax.com nezita rako nezera rako sechidzidzo.
Verenga zvakare izvi: CAR T Cell kurapa muIndia
Side mhedzisiro yeCAR T-Cell kurapa
Iyo yakajairwa mhedzisiro mhedzisiro yeCAR T-cell kurapa inosanganisira:
- Cytokine kuburitsa chirwere
Mune zvimwe zviitiko, varwere vanogona kuita zviratidzo zvakaita sefuru zvakaita sefivha, kutonhora, kutemwa nemusoro, kuda kurutsa, kurutsa, zvigaro zvakasununguka, uye mhasuru kana marwadzo ekubatana. Izvo zvinogona zvakare kukonzera yakaderera BP, kunetseka mukufema, uye nekukurumidza moyo kurovera. Iyi mhedzisiro inokonzerwa nekusunungurwa kwema cytokines nemaseru ekudzivirira panguva yeCAR T-cell kurapa. Zviratidzo izvi zvinowanzo nyoro, asi zvinogona kuve zvakakomba uye kutyisidzira hupenyu kune vamwe varwere. - Zviitiko zve Neurological
Zviitiko zveeurological zvinogona kuitika uye zvinogona kuve zvakakomba mune vamwe varwere. Zviitiko zvakadaro zvinosanganisira encephalopathy (kukuvara kwehuropi uye kusashanda zvakanaka), kuvhiringidzika, kunetsekana kutaura, kushushikana, kufenda, kukotsira, kwakachinja mamiriro ekuziva uye kurasikirwa kwechiyero. - Neutropaenia uye Anemia
Vamwe varwere vanogona kukura neutropenia kana yakaderera chena masero kuverenga. Saizvozvo, kupererwa neropa kana kushomeka tsvuku masero eropa kuverenga kunogona kuitikawo nekuda kwerapi iyi.
Neraki, yakawanda yemhedzisiro mhedzisiro inowanzo gadzirisa yega kana inogona kutarisirwa nekushandiswa kwe mishonga.
Inoshanda zvakadii CAR T-Cell kurapa?
CAR T-cell therapy for the treatment of lymphoma and other blood cancers has shown promising outcomes. Since CAR T-cell treatment, many patients who had previously relapsed blood tumours had promising results and no evidence of cancer. It has also aided in the rehabilitation of patients who have previously failed to respond to most traditional cancer therapies.
Zvisinei, zvidzidzo zvenguva yakareba zvevanhu vakawanda vane varwere zvinodiwa kuti zvibatsire kushanda kwekurapa uku. Kuedza kukuru-kwechiyero kwaizobatsirawo mukuona mukana wemhedzisiro uye nzira dzakakodzera dzekugadzirisa nazvo.
Zvipatara zvinopa CAR T-cell therapy muMalaysia
- Sunway Medical Center, Selangor
- Columbia Asia Hospital, Kuala Lumpur
Ndingaite sei kurapwa muMalaysia?